Pancreas Cancer | Medical XPRT
Articles & Whitepapers
-
Unveiling the Role of CD73: A Key Player in Immune Regulation and Beyon
What is CD73? CD73, also known as ecto-5′-nucleotidase, is a groundbreaking immunoinhibitory protein that assumes a pivotal role in tumor growth and metastasis. Its primary function revolves around converting extracellular ATP into immunosuppressive adenosine, working in tandem with CD39 within normal tissues to curtail excessive immune reactions. However, this mechanism is often hijacked ...
-
What are the Possibilities for ADCs Targeting Trop2?
Antibody drug conjugate (ADC) research involves more and more targets, such as HER-2, Trop-2, Claudin-18.2, B7-H3 and B7-H4, etc. Trop-2 is a transmembrane glycoprotein. Its high expression is ...
News
-
CGTLive Interview: New Frontiers in Allogeneic Cell Therapy
Cartherics’ CEO, Professor Alan Trounson, was recently interviewed by CGTLive, to discuss the company’s development of NK cell, T-cell and macrophage cell therapies for various solid tumours. Cartherics is using its induced pluripotent ...
Bristol-Myers Squibb Awards First “Golden Tickets” for LabCentral to PanTher, Suono Bio
Carrick Therapeutics and The Menarini Group Announce Clinical Trial Collaboration to Evaluate Samuraciclib and Elacestrant Combination
xCures partners with RenovoRx to assist patients in accessing RenovoRx’s TIGeR-PaC study
ITM Receives FDA Fast Track Designation for Radionuclide Therapy Candidate ITM-11 (n.c.a. 177Lu-edotreotide) in Neuroendocrine Tumors (GEP-NETs)
Equipment & Solutions
-
Showcase
Neo-Epitope-Based Vaccine
Tedopi®, OSE Immunotherapeutics’s most advanced product and therapeutic neo-epitope-based vaccine, is a proprietary combination of nine optimized neo-epitopes, selected and optimized from 5 tumoral antigens to activate specifically T cells, plus one epitope giving universal helper T cell response targeting T cell activation.